RenovoRx, Inc.
RNXTHealthcare|Biotechnology|US
$1.13
-0.06 (-5.04%)
DCF Value
$0.89
Tangible Book / Share
$0.19
Cash / Share
$0.22
About
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Stock Price
+17.0%(1Y)
1M
-15.0%
3M
+0.9%
6M
+30.8%
YTD
+34.5%
1Y
+13.4%
3Y
-0.9%
5Y
-78.8%
Pipeline Summary
4 total trials1
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
Completed: 2Active: 1Recruiting: 1
Active Trials (2)
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
NCT03257033Locally Advanced Pancreatic Cancer
Phase 3Active
Enrollment: 190 participants
PumaRx Registry Trial
NCT06805461Solid Tumors
Recruiting
Enrollment: 1,000 participants
Key Facts
Market Cap$51.0M
Employees17 (+70% YoY)
CEOShaun R. Bagai
IPO DateAug 26, 2021
Beta0.97
52-Week Range$0.7006 – $2.59
Avg Volume658,668
ExchangeNASDAQ
Websiterenovorx.com
Ownership
Float96.3%
Shares Outstanding45.1M
Recent Insider Trades
Macfarlane K. AngelaAWARD
Oct 1, 202655,924 shares @ $1.55
Spiegel Robert J.AWARD
Oct 1, 202655,924 shares @ $1.55
RYAN UNA SAWARD
Oct 1, 202655,924 shares @ $1.55
Marton LaurenceAWARD
Oct 1, 202655,924 shares @ $1.55
VOLL MARKAWARD
Sep 10, 202680,000 shares
Peers
Recent News
RenovoRx Q3 Earnings Call Highlights
Nov 6, 2026 · marketbeat.com
RenovoRx, Inc. (RNXT) Q3 2026 Earnings Call Transcript
Nov 6, 2026 · seekingalpha.com
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates
Nov 5, 2026 · zacks.com
RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million
Nov 5, 2026 · globenewswire.com
RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
Oct 28, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:32 AM